MarketPulse

neuroprotective therapy

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis to Present Pivotal Optic Neuritis Data as Privosegtor Advances Toward FDA Review

Oculis presents Phase 2 data for Privosegtor, an FDA Breakthrough-designated optic neuritis therapy showing improved visual acuity and reduced nerve damage, advancing toward Phase 3 registration trial.
OCSOCSAWFDA Breakthrough Therapy DesignationPrivosegtor
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis to Showcase Optic Neuritis Data as Privosegtor Advances to Pivotal Trials

Oculis presents Phase 2 ACUITY trial results for Privosegtor at neuro-ophthalmology conference, showing vision improvements. Breakthrough therapy advances to registrational PIONEER program.
OCSOCSAWPrivosegtoroptic neuritis